Active Biotech invites to Capital Markets Day

May 18, 2010 10:00 (CEST)

Active Biotech invites analysts, investors and media to Capital Markets Day on June 10, 2010.


When:              Thursday, June 10, 2010 at 2-4 p.m. CET.

Where:             IVA Conference center, Grev Turegatan 16, 

                        Stockholm, Sweden  

To attend:         Please send name & contact details to or call
+46 (0)46 19 20 00, no later than June 7

Active Biotech  participants:

                        Tomas Leanderson, President & CEO

                        Hans Kolam, CFO

                        Göran Forsberg, VP Investor Relations & Business Development

                        Helén Tuvesson, Head of Preclinical development


Program:          Overview of Active Biotech's project portfolio



The Capital Markets Day will also be available to follow via Active Biotech's website




For further information, please contact:

Hans Kolam, CFO

Phone: +46 (0)46 19 20 44




About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit for more information.


Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on May 18, 2010.



Active Biotech AB (org. no. 556223-9227)

P.O. Box 724, SE-220 07 Lund, Sweden

Tel +46 46-19 20 00

Fax +46 46-19 11 00


Active Biotech invites to Capital Markets Day